Vascular endothelial cell growth factor antagonists and uses...

Details Vascular endothelial cell growth factor antagonists and uses... Vascular endothelial cell growth factor antagonists and uses...

2011-08-16

2011-08-16

Harris, Alana M. (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C424S134100, C424S192100, C530S373000, C530S402000

Reexamination Certificate

active

07998931

ABSTRACT:
The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.

REFERENCES:
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 5036003 (1991-07-01), Olander et al.
patent: 5306710 (1994-04-01), Wei
patent: 5518999 (1996-05-01), Nakamura et al.
patent: 5955311 (1999-09-01), Rockwell et al.
patent: 6093740 (2000-07-01), Jirousek et al.
patent: 6114320 (2000-09-01), Aiello et al.
patent: 6177401 (2001-01-01), Ullrich et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7060269 (2006-06-01), Baca et al.
patent: 2005/0053599 (2005-03-01), Van Bruggen et al.
patent: 2005/0244405 (2005-11-01), Van Bruggen et al.
patent: 2007/0110755 (2007-05-01), Ferrara et al.
patent: 2008/0181900 (2008-07-01), Ferrara et al.
patent: 2008/0187534 (2008-08-01), Baca et al.
patent: 2008/0226629 (2008-09-01), Baca et al.
patent: 2008/0299116 (2008-12-01), Van Bruggen et al.
patent: 2008/0311118 (2008-12-01), Van Bruggen et al.
patent: 2009/0081232 (2009-03-01), Kim et al.
patent: 2355976 (1999-12-01), None
patent: 1238986 (2002-09-01), None
patent: 1140173 (2005-08-01), None
patent: 04506659 (1992-11-01), None
patent: 08502514 (1996-03-01), None
patent: WO 92/14748 (1992-09-01), None
patent: 94/10202 (1994-05-01), None
patent: WO 96/30046 (1996-10-01), None
patent: WO 97/40831 (1997-11-01), None
patent: WO 97/44453 (1997-11-01), None
patent: WO 97/49408 (1997-12-01), None
patent: 98/16551 (1998-04-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/48795 (1998-11-01), None
patent: WO 98/52577 (1998-11-01), None
patent: WO 00/27414 (2000-05-01), None
patent: WO 00/29584 (2000-05-01), None
patent: WO 00/37502 (2000-06-01), None
Severinghaus, J.W., et al. J. Appl. Physiol., 79(2): 375-379, 1995.
Heiss, J. D., et al., Journal of Clinical Investigation, 98(6): 1400-1408, 1996.
Aiello, L.P., et al. Proc. Natl. Acad. Sci., 92: 10457-10461, 1995.
Jin, D.P., et al. Lymphatic Research and Biology, 7(1): 47-57, 2009.
Kajiya, K. et al., Journal of Investigative Dermatology, 129: 1292-1298, 2009.
Nag, S., et al. Journal of Neuropathology and Experimental Neurology, 56(8): 912-921, 1997.
Berkman et al., “Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms”J. Clin. Invest.91:153-159 (Jan. 1993).
Risau, W., “Molecular biology of blood-brain barrier ontogenesis and function”Acta Neurochirurgica(abstract only) 60:109-112 (1994).
Taber's Cyclopedic Medical Dictionary, 16th edition, Philadelphia:F.A. Davis Company pp. 742 (1989).
van Bruggen et al., “VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain”Journal of Clinical Investigation104(11):1613-1620 (Dec. 1999).
U.S. Appl. No. 09/218,418, Dec. 22, 1998, Van Bruggen et al.
U.S. Appl. No. 09/718,694, Nov. 21, 2000, Van Bruggen et al.
Genentech, Inc., 2009, AVASTIN™ (Bevacizumab) Labeling Text, U.S. BL 125085/169 Amendment.
Adamis et al., 1996, “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate,” Arch. Ophthalmol., 114:66-71.
Aiello et al., 1994, “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” The New England Journal of Medicine, 331(22):1480-1486.
Aiello et al., 1996, “Vascular endothelial growth factor (VEGF) increases retinal vascular permeability in vivo,” Investigative Ophthalmology & Visual Science, 37(3), Abstract 578-B490.
Aiello et al., 1997, “Vascular Endothelial Growth Factor-Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform-Selective Inhibitor,” Diabetes, 46:1473-1480.
Ambati et al., 1997, “Elevated γ-Aminobutyric Acid, Glutamate, and Vascular Endothelial Growth Factor Levels in the Vitreous of Patients With Proliferative Diabetic Retinopathy,” Arch. Ophthalmol., 115:1161-1166.
Arimura et al., 1997, “Two cases of POEMS syndrome with increased vascular endothelial growth factor (VEGF),” Clin. Neurol., 37(9):817-823 (in Japanese with English abstract).
Arimura et al., 1998, “Characteristic edema in Crow-Fukase syndrome,” Neurol. Med., 49:248-249 (in Japanese).
Arimura et al., 1998, “The pathophysiology of Crow-Fukase syndrome,” Neuroimm., 6(2)1-6 (in Japanese with English abstract).
Asano et al., 1998, “An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo,” Hybridoma, 17(2):185-190.
Bae et al., 2000, “Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis,” The Journal of Biological Chemistry, 275(18):13588-13596.
Bae et al,, 2005, “Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis,” Clin Cancer res., 11(7):2651-2661.
Baker et al., 1995, “Elevated Serum Levels of Vascular Endothelial Growth Factor in Patients With Preeclampsia,” Obstetrics & Gynecology, 86(5):815-821.
Barleon et al., “Differential Expression of the Two VEGF Receptors fit and KDR in Placenta and Vascular Endothelial Cells,” J. Cell Biochem., 1994,54(1):56-66.
Bates, D.O. et al., 1996. “Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels,” Am. J. Physiol. 271: H2520-H2528.
Batzdorf, 1976, “The management of cerebral edema in pediatric practice,” Pediatrics, 58:78-87.
Bennett et al., 1991, “Extracellular Domain-IgG Fusion Proteins for Three Human Natriuretic Peptide Receptors. Hormone Pharmacology and Application to Solid Phase Screening of Synthetic Peptide Antisera,” J. Biol. Chem., 266(34):23060-23067.
Brauchle et al., 1996, “Ultraviolet Band H2O 2 Are Potent Inducers of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes,” J. Biol. Chem., 271(36):21793-21797.
Brekken et al., 1998, “Vascular endothelial growth factor as a marker of tumor endothelium,” Cancer Research, 58:1952-1959.
Brekken et al., 2000, “Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice,” Cancer Research, 60:5117-5124.
Burgess et al., 1989, “The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins,” Annu. Rev. Biochem., 58:575-606.
Chen et al., 1986, “A Model of Focal Ischemic Stroke in the Rat: Reproducible Extensive Cortical Infarction,” Stroke, 17(4):738-743.
Cheng et al., 1997, “Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121and VEGF165but not VEGF189,” Proc. Natl. Acad. Sci. USA, 94:12081-12087.
Chisholm et al., 1995, “DNA Cloning 4: A Practical Approach,” Mammalian Systems, pp. 1-39.
Collins et al., 1993, “Characterization of the Increase in Vascular Permeability Induced by Vascular Permeability Factor in vivo,” Br. J. Pharmacol., 109:195-199.
Connolly et al., 1989, “Human Vascular Permeability Factor. Isolation from U937 Cells,” J Biol. Chem., 264(33):20017-20024.
Connolly et al., 1989, “Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis,” J. Clin. Invest., 84(5):1470-1478.
Criscuolo, 1993, “Clinical Neurosciences in the Decade of the Brain Hypotheses in Neuro-Oncology: The Genesis of Peritumoral Vasogenic Brain Edema and Tumor Cysts: A Hypothetical Role for Tumor-Derived Vascular Permeability Factor,

Affiliated with

Also associated with

Rating

Vascular endothelial cell growth factor antagonists and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vascular endothelial cell growth factor antagonists and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascular endothelial cell growth factor antagonists and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2709828